Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 12/20 | 0.47 |
| ▸ | MMP2 | P08253 | 10/20 | 0.47 |
| ▸ | MMP13 | P45452 | 7/20 | 0.47 |
| ▸ | MMP1 | P03956 | 7/20 | 0.47 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.46 |
| ▸ | MMP16 | P51512 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.44 |
| ▸ | MMP14 | P50281 | 4/20 | 0.44 |
| ▸ | MMP12 | P39900 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620444 | 1.00 | ADAMTS4 (0.58) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL3613169 | 1.00 | ADAMTS4 (0.58) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL3099546 | 0.84 | ADAMTS4 (0.54) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL3610021 | 0.84 | ADAMTS4 (0.54) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL3609984 | 0.84 | ADAMTS4 (0.54) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL6501034 | 0.83 | ADAMTS4 (0.52) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL27784184 | 0.82 | ADAMTS4 (0.51) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL6505810 | 0.82 | ADAMTS4 (0.51) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL3092467 | 0.82 | ADAMTS4 (0.51) | ADAMTS4MMP9MMP2MMP13MMP1 | |
| SCHEMBL3092924 | 0.76 | MAPT (0.46) | ADAMTS4MMP2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| EP-1912634-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Healthcare, LLC (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007016538-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016538-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | ADAMTS4 3197/4885MMP9 2453/4885MMP2 2401/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | ADAMTS4 3197/4885MMP9 2453/4885MMP2 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.